Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 1
2018 1
2019 1
2021 3
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial.
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, Neuberger A, Ghanem-Zoubi N, Santoro A, Eliakim-Raz N, Pertzov B, Steinmetz T, Stern A, Dickstein Y, Maroun E, Zayyad H, Bishara J, Alon D, Edel Y, Goldberg E, Venturelli C, Mussini C, Leibovici L, Paul M; Bacteremia Duration Study Group. Yahav D, et al. Among authors: koppel f. Clin Infect Dis. 2019 Sep 13;69(7):1091-1098. doi: 10.1093/cid/ciy1054. Clin Infect Dis. 2019. PMID: 30535100 Clinical Trial.
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Paul M, et al. Among authors: koppel f. Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16. Lancet Infect Dis. 2018. PMID: 29456043 Clinical Trial.
Risk factors for functional decline among survivors of Gram-negative bloodstream infection: A prospective cohort study.
Turjeman A, Koppel F, Franceschini E, Yahav D, Dolci G, Babich T, Bitterman R, Neuberger A, Ghanem-Zoubi N, Santoro A, Eliakim-Raz N, Pertzov B, Stern A, Dickstein Y, Maroun E, Zayyad H, Meschiari M, Bishara J, Goldberg E, Venturelli C, Mussini C, Paul M, Leibovici L. Turjeman A, et al. Among authors: koppel f. PLoS One. 2021 Nov 17;16(11):e0259707. doi: 10.1371/journal.pone.0259707. eCollection 2021. PLoS One. 2021. PMID: 34788325 Free PMC article.
Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen).
Bitterman R, Koppel F, Mussini C, Geffen Y, Chowers M, Rahav G, Nesher L, Ben-Ami R, Turjeman A, Huberman Samuel M, Cheng MP, Lee TC, Leibovici L, Yahav D, Paul M. Bitterman R, et al. Among authors: koppel f. BMJ Open. 2021 Feb 8;11(2):e040210. doi: 10.1136/bmjopen-2020-040210. BMJ Open. 2021. PMID: 33558347 Free PMC article.
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity.
Daitch V, Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Cavezza G, Adler A, Dickstein Y, Pavleas I, Zampino R, Bitterman R, Zayyad H, Koppel F, Zak-Doron Y, Levi I, Babich T, Turjeman A, Ben-Zvi H, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Daitch V, et al. Among authors: koppel f. BMC Infect Dis. 2021 Mar 31;21(1):309. doi: 10.1186/s12879-021-05995-y. BMC Infect Dis. 2021. PMID: 33789574 Free PMC article.
External Validity of a Randomized Controlled Trial on Duration of Antibiotics for the Treatment of Gram-Negative Bacteremia.
Turjeman A, Koppel F, Franceschini E, Yahav D, Dolci G, Bacca E, Babich T, Khazem E, Baum E, Nassar R, Bitterman R, Dishon-Benatta Y, Hassoun-Kheir N, Santoro A, Eliakim-Raz N, Poran I, Pertzov B, Stern A, Dickstein Y, Maroun E, Raines M, Meschiari M, Bishara J, Goldberg E, Venturelli C, Sarti M, Mussini C, Paul M, Leibovici L. Turjeman A, et al. Among authors: koppel f. Gerontology. 2022 Oct 21:1-9. doi: 10.1159/000526480. Online ahead of print. Gerontology. 2022. PMID: 36273449
A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection.
Howard-Anderson J, Dai W, Yahav D, Hamasaki T, Turjeman A, Koppel F, Franceschini E, Hill C, Sund Z, Chambers HF, Fowler VG Jr, Boucher HW, Evans SR, Paul M, Holland TL, Doernberg SB. Howard-Anderson J, et al. Among authors: koppel f. Open Forum Infect Dis. 2022 Apr 9;9(6):ofac140. doi: 10.1093/ofid/ofac140. eCollection 2022 Jun. Open Forum Infect Dis. 2022. PMID: 35615299 Free PMC article.
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M; AIDA consortium. Dickstein Y, et al. Among authors: koppel f. BMJ Open. 2016 Apr 20;6(4):e009956. doi: 10.1136/bmjopen-2015-009956. BMJ Open. 2016. PMID: 27098822 Free PMC article. Clinical Trial.